Announcing FierceMedicalDevices

"When are you launching FierceMedicalDevices?" 

That's the number one request the Fierce Life Sciences team receives from our readers. You asked loudly, and now I have an answer: We're launching tomorrow, Wednesday, March 24.

Our goal is simple: Be the first place you turn for medical devices and diagnostics news and insight. We've designed a weekly report readers will find relevant, timely, and most importantly, Fierce. As a current FierceBiotech subscriber, you're entitled to an easy one-click sign-up by clicking below:

Click here to activate your complimentary FierceMedicalDevices subscription - one click.

FierceMedicalDevices will be delivered every Wednesday by e-mail, and FierceMedicalDevices.com will be updated throughout the week as news breaks. Real-time news consumers will find @FierceMedDev on Twitter another valuable resource.

We've got our eyes on key regulatory decisions, clinical studies, research and development, post-marketing, and dealmaking in medical devices and diagnostics. But we also need your news and tips: Maureen Martino and Liz Jones will lead our editorial coverage. Readers and key industry influencers should reach out directly to them.

Your feedback led to the launch of this publication, and your participation in the Fierce community is greatly appreciated. If you're involved in the medical devices or diagnostics fields, we think you're going to love our new publication.

- Arsalan Arif (e-mail me | follow me on Twitter)
Group Publisher, FierceMarkets Life Sciences

PS: Click here for one-click sign-up to FierceMedicalDevices. Your first newsletter will be delivered Wednesday, March 24.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.